未找到相关数据
Phase I/II safety and preliminary efficacy of PM1022, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors
被引：0
作者：
Xue, Junli
Zhang, Yan
Hu, Xudong
Zhao, Wei
Sun, Yuping
Li, Qun
Jin, Xiaoying
Xue, Liqiong
Ge, Xiaoxiao
Lin, Fengjuan
Tang, Wenbo
Zhou, Jiuli
Guo, Ye
机构：
[1] Shanghai East Hosp, Shanghai, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
[3] Tongji Univ, Shanghai East Hosp, Sch Med, Shanghai, Peoples R China
[4] Shandong First Med Univ, Shandong Canc Hosp, Jinan, Peoples R China
[5] Shanghai East Hosp, Tongji Univ, Sch Med, Dept Med Oncol, Shanghai, Peoples R China
[6] Tongji Univ, Dept Oncol, Shanghai East Hosp, Sch Med, Shanghai, Peoples R China
[7] Tongji Univ, Shanghai East Hosp, Shanghai, Peoples R China
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14694
引用
收藏
页数：1
相关论文